Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A novel GLP-1 and amylin receptor agonist reduced HbA1c ...
A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Vigil Neuroscience, Inc. announced positive Phase 1 clinical trial results for VG-3927, a potential once-daily oral therapy for Alzheimer’s disease (AD). The trial demonstrated favorable safety, ...
Cidara Therapeutics soared 250% after strong Phase 2b NAVIGATE trial results for CD388, a novel antiviral for flu prophylaxis. CD388 demonstrated up to 76% efficacy, outperforming many traditional flu ...
A Metropolitan Transportation Authority rendering shows a conceptual interior of a future Second Avenue Subway station in Harlem, illustrating platform circulation, train clearances and passenger flow ...
Equinor ASA, Shell PLC and TotalEnergies SE have approved the second phase of the Northern Lights carbon, capture and storage (CCS) project in Norway with a NOK 7.5 billion ($700 million) investment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results